Works matching IS 2574173X AND DT 2023 AND VI 43 AND IP 2


Results: 16
    1
    2
    3
    4
    5
    6
    7

    Systemic administration of the antisense oligonucleotide NS‐089/NCNP‐02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial.

    Published in:
    Neuropsychopharmacology Reports, 2023, v. 43, n. 2, p. 277, doi. 10.1002/npr2.12335
    By:
    • Ishizuka, Takami;
    • Komaki, Hirofumi;
    • Asahina, Yasuko;
    • Nakamura, Harumasa;
    • Motohashi, Norio;
    • Takeshita, Eri;
    • Shimizu‐Motohashi, Yuko;
    • Ishiyama, Akihiko;
    • Yonee, Chihiro;
    • Maruyama, Shinsuke;
    • Hida, Eisuke;
    • Aoki, Yoshitsugu
    Publication type:
    Article
    8
    9
    10

    Serum soluble triggering receptor expressed on myeloid cells‐2 was not altered by rTMS in patients with treatment‐resistant depression.

    Published in:
    Neuropsychopharmacology Reports, 2023, v. 43, n. 2, p. 222, doi. 10.1002/npr2.12332
    By:
    • Tateishi, Hiroshi;
    • Matsushima, Jun;
    • Kunitake, Hiroko;
    • Imamura, Yoshiomi;
    • Kunitake, Yutaka;
    • Murakawa, Toru;
    • Mawatari, Seiji;
    • Kojima, Ryohei;
    • Fujii, Yuka;
    • Kikuchi, Jun;
    • Fukuchi, Junko;
    • Sakemura, Yuta;
    • Shiraishi, Takumi;
    • Nagahama, Chika;
    • Maekawa, Toshihiko;
    • Asami, Toyoko;
    • Mizoguchi, Yoshito;
    • Monji, Akira
    Publication type:
    Article
    11
    12
    13
    14

    Management of unspecified anxiety disorder: Expert consensus.

    Published in:
    Neuropsychopharmacology Reports, 2023, v. 43, n. 2, p. 188, doi. 10.1002/npr2.12323
    By:
    • Sakurai, Hitoshi;
    • Inada, Ken;
    • Aoki, Yumi;
    • Takeshima, Masahiro;
    • Ie, Kenya;
    • Kise, Morito;
    • Yoshida, Eriko;
    • Tsuboi, Takashi;
    • Yamada, Hisashi;
    • Hori, Hikaru;
    • Inada, Yasushi;
    • Shimizu, Eiji;
    • Mishima, Kazuo;
    • Watanabe, Koichiro;
    • Takaesu, Yoshikazu
    Publication type:
    Article
    15
    16

    Issue Information.

    Published in:
    Neuropsychopharmacology Reports, 2023, v. 43, n. 2, p. 171, doi. 10.1002/npr2.12264
    Publication type:
    Article